Three therapies (belantamab mafodotin and two CAR-T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel) targeting the BCMA have been approved for the treatment of MM patients who have previously received immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies. Here, TNFRSF17 is linked to Miyoshi myopathy.